In EGFR-mutated, advanced NSCLC, osimertinib showed longer progression-free survival than gefitinib or erlotinib (18.9 vs. 10.2 months; hazard ratio, 0.46; 95% CI, 0.37–0.57; P < 0.001) (34). Here, EGFR is linked to non-small cell lung carcinoma.